Last reviewed · How we verify
Stempeucel®
Stempeucel® is an allogeneic mesenchymal stem cell therapy that promotes tissue regeneration and reduces inflammation through paracrine signaling and immunomodulation.
Stempeucel® is an allogeneic mesenchymal stem cell therapy that promotes tissue regeneration and reduces inflammation through paracrine signaling and immunomodulation. Used for Critical limb ischemia, Diabetic foot ulcers.
At a glance
| Generic name | Stempeucel® |
|---|---|
| Sponsor | Cell Biopeutics Resources Sdn Bhd |
| Drug class | Allogeneic mesenchymal stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Orthopedics |
| Phase | FDA-approved |
Mechanism of action
The product consists of ex vivo expanded bone marrow-derived mesenchymal stem cells that secrete bioactive factors including cytokines and growth factors. These cells modulate the immune response, reduce inflammatory markers, and promote angiogenesis and tissue repair in damaged tissues. The mechanism relies on the therapeutic properties of living cells rather than a single molecular target.
Approved indications
- Critical limb ischemia
- Diabetic foot ulcers
Common side effects
- Injection site reactions
- Fever
- Infection
Key clinical trials
- Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease (PHASE4)
- Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease (PHASE4)
- A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stempeucel® CI brief — competitive landscape report
- Stempeucel® updates RSS · CI watch RSS
- Cell Biopeutics Resources Sdn Bhd portfolio CI